Stephen W. Reese

Stephen W. Reese

Auto-generated profile, based on publicly available information

Stephen W. Reese

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Journal of Urology
Verified
Journal Article
Closed access
HZHongjuan Zhao
Hongjuan Zhao
MCMarc A. Coram
Marc A. Coram
RNRosalie Nolley
Rosalie Nolley
SRStephen W. Reese
Stephen W. Reese
SYSarah R. Young
Sarah R. Young
DPDonna M. Peehl
Donna M. Peehl
AR-V7, a ligand independent splice variant of androgen receptor, may support the growth of castration resistant prostate cancer and have prognostic value. Another variant, AR-V1, interferes with AR-V7 activity. We investigated whether AR-V7 or V1 expression would predict biochemical recurrence in men at indeterminate (about 50%) risk for progression following radical prostatectomy. AR-V7 and V1 transcripts in a mixed grade cohort of 53 men in whom cancer contained 30% to 70% Gleason grade 4/5 and in a grade 3 only cohort of 52 were measured using a branched chain DNA assay. Spearman rank correlations of the transcripts, and histomorphological and clinical variables were determined. AR-V7 and V1 levels were assessed as determinants of recurrence in the mixed grade cohort by logistic regression and survival analysis. The impact of TMPRSS2-ERG gene fusion on prognosis was also evaluated. Neither AR-V7 nor V1 levels in grade 3 or 4/5 cancer in the mixed grade cohort were associated with recurrence or time to recurrence. However, AR-V7 and V1 inversely correlated with serum prostate specific antigen and positively correlated with age. The AR-V1 level in grade 3 cancer in the grade 3 only cohort was higher than in grade 3 or grade 4/5 components of mixed grade cancer. TMPRSS2-ERG fusion was not associated with AR-V7, AR-V1 or recurrence but it was associated with the percent of grade 4/5 cancer. The AR-V1 or V7 transcript level does not predict recurrence in patients with high grade prostate cancer at indeterminate risk for progression. Grade 3 cancer in mixed grade tumors may differ from 100% grade 3 cancer, at least in AR-V1 expression.

30 March 2020 in BJU International
Verified
Journal Article
Open access
PDF file
ECEugene B. Cone
Eugene B. Cone
MMMaya Marchese
Maya Marchese
SRStephen W. Reese
Stephen W. Reese
MSMaxine Sun
Maxine Sun
Junaid NabiJunaid Nabi
Junaid Nabi
QTQuoc‐Dien Trinh
Quoc‐Dien Trinh
Induction of hypogonadism is standard‐of‐care for advanced prostate cancer. Gonadotropic releasing hormone (GnRH) agonists and antagonists lower testosterone with similar efficacy but may be associated with increased cardiovascular risk. In small randomized controlled trials (RCTs) comparing the two, one found no difference, whereas another and a non‐randomized study found a difference among individuals with cardiac comorbidities.[1‐3], Given this discrepancy, and with cardiovascular disease the most common cause of non‐cancer death in prostate cancer patients,[4] we compared reporting of cardiac events in patients treated with GnRH agonists and antagonists using disproportionality analysis.

1 April 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
SRStephen W. Reese
Stephen W. Reese
EJEmily Ji
Emily Ji
Marco PaciottiMarco Paciotti
Marco Paciotti
Jeffrey J LeowJeffrey J Leow
Jeffrey J Leow
DMDavid A. Mahvi
David A. Mahvi
MMMatthew Mossanen
Matthew Mossanen

8 June 2015 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
SRStephen Reese
Stephen Reese
KGKenneth Grundfast
Kenneth Grundfast

1 October 2021 in European Urology Oncology
Verified
Journal Article
Closed access
SRStephen W. Reese
Stephen W. Reese
KTKarl H. Tully
Karl H. Tully
JNJunaid Nabi
Junaid Nabi
Marco PaciottiMarco Paciotti
Marco Paciotti
WCWesley H. Chou
Wesley H. Chou
MLMuhieddine Labban
Muhieddine Labban

1 October 2020 in Gastroenterology
Verified
Journal Article
Closed access
SRStephen W. Reese
Stephen W. Reese
MMMaya Marchese
Maya Marchese
JMJulia McNabb-Baltar
Julia McNabb-Baltar